{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T02:47:25Z","timestamp":1768013245045,"version":"3.49.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T00:00:00Z","timestamp":1575331200000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the Guangzhou Key Medical Discipline Construction Project","award":["No. 2017"],"award-info":[{"award-number":["No. 2017"]}]},{"name":"Guangdong Science and Technology Plan Project","award":["No. 20160918"],"award-info":[{"award-number":["No. 20160918"]}]},{"name":"Guangzhou Science Technology and Innovation Commission","award":["No. 2014Y2-00152"],"award-info":[{"award-number":["No. 2014Y2-00152"]}]},{"name":"Guangzhou Science Technology and Innovation Commission","award":["No. 2014Y2-00548"],"award-info":[{"award-number":["No. 2014Y2-00548"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Bladder hyperthermic intracavitary chemotherapy (HIVEC) has good effectiveness for bladder cancer, but conventional HIVEC systems lack precision and convenient application. To test the safety of a new HIVEC device (BR-TRG-II-type) in pigs and to perform a preliminary clinical trial in patients with bladder cancer.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>This device was tested on six pigs to optimize the temperature and time parameters. Then, 165 patients (HIVEC after transurethral resection (TUR), <jats:italic>n<\/jats:italic>\u2009=\u2009128; or HIVEC, <jats:italic>n<\/jats:italic>\u2009=\u200937) treated between December 2006 and December 2016 were recruited. Mitomycin C (MMC) was the chemotherapeutic agent. A serum pharmacokinetic study was performed. The primary endpoints were tumor recurrence, disease-free survival (DFS), and cumulative incidence rate (CIR) during follow-up. The adverse effects were graded.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>The animal experiment showed that 45\u2009\u00b0C for 1\u2009h was optimal. HIVEC was successful, with the infusion tube temperature stably controlled at about 45\u2009\u00b0C, and outlet tube temperature of about 43\u2009\u00b0C in all patients, for three sessions. Serum MMC levels gradually increased during HIVEC and decreased thereafter. The mean DFS was 39\u2009\u00b1\u20093.21\u2009months (ranging from 8 to 78\u2009months), and the DFS rate was 89.1% during follow-up. No adverse events occurred.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>The use of the BR-TRG-II-type HIVEC device is feasible for the treatment of bladder cancer. Future clinical trials in patients with different stages of bladder cancer will further confirm the clinical usefulness of this device.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Trial registration<\/jats:title>\n<jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/chictr.org.cn\">chictr.org.cn<\/jats:ext-link>: ChiCTR1900022099 (registered on Mar. 252,019). Retrospectively registered.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12894-019-0543-8","type":"journal-article","created":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T16:04:01Z","timestamp":1575389041000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Development of a high-precision bladder hyperthermic intracavitary chemotherapy device for bladder cancer and pharmacokinetic study"],"prefix":"10.1186","volume":"19","author":[{"given":"Mingchen","family":"Ba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuzhong","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanfeng","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinbing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunpeng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinuo","family":"Tu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bahuo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanbo","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,3]]},"reference":[{"issue":"1","key":"543_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.20138","volume":"62","author":"R Siegel","year":"2012","unstructured":"Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10\u201329.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"543_CR2","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.juro.2016.05.032","volume":"196","author":"DF Penson","year":"2016","unstructured":"Penson DF. Re: effectiveness of adjuvant chemotherapy for locally advanced bladder Cancer. J Urol. 2016;196(2):352\u20134.","journal-title":"J Urol"},{"issue":"3","key":"543_CR3","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3233\/BLC-160056","volume":"2","author":"L Douglass","year":"2016","unstructured":"Douglass L, Schoenberg M. The future of Intravesical drug delivery for non-muscle invasive bladder Cancer. Bladder Cancer. 2016;2(3):285\u201392.","journal-title":"Bladder Cancer"},{"issue":"9","key":"543_CR4","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s11934-016-0625-z","volume":"17","author":"R Veeratterapillay","year":"2016","unstructured":"Veeratterapillay R, Heer R, Johnson MI, Persad R, Bach C. High-risk non-muscle-invasive bladder Cancer-therapy options during Intravesical BCG shortage. Curr Urol Rep. 2016;17(9):68.","journal-title":"Curr Urol Rep"},{"key":"543_CR5","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1186\/s12885-015-1431-6","volume":"15","author":"D Hayne","year":"2015","unstructured":"Hayne D, Stockler M, McCombie SP, Chalasani V, Long A, Martin A, et al. BCG+MMC trial: adding mitomycin C to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: a randomised phase III trial (ANZUP 1301). BMC Cancer. 2015;15:432.","journal-title":"BMC Cancer"},{"issue":"3","key":"543_CR6","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3109\/02656736.2014.882021","volume":"30","author":"BA Inman","year":"2014","unstructured":"Inman BA, Stauffer PR, Craciunescu OA, Maccarini PF, Dewhirst MW, Vujaskovic Z. A pilot clinical trial of intravesical mitomycin-C and external deep pelvic hyperthermia for non-muscle-invasive bladder cancer. Int J Hyperth. 2014;30(3):171\u20135.","journal-title":"Int J Hyperth"},{"issue":"6","key":"543_CR7","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1111\/j.1464-410X.2010.09654.x","volume":"107","author":"R Colombo","year":"2011","unstructured":"Colombo R, Salonia A, Leib Z, Pavone-Macaluso M, Engelstein D. Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC). BJU Int. 2011;107(6):912\u20138.","journal-title":"BJU Int"},{"issue":"3","key":"543_CR8","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1046\/j.0306-5251.2001.01449.x","volume":"52","author":"R Paroni","year":"2001","unstructured":"Paroni R, Salonia A, Lev A, Da Pozzo LF, Cighetti G, Montorsi F, et al. Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma. Br J Clin Pharmacol. 2001;52(3):273\u20138.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"543_CR9","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S1040-8428(03)00076-3","volume":"47","author":"R Colombo","year":"2003","unstructured":"Colombo R, Salonia A, Da Pozzo LF, Naspro R, Freschi M, Paroni R, et al. Combination of intravesical chemotherapy and hyperthermia for the treatment of superficial bladder cancer: preliminary clinical experience. Crit Rev Oncol Hematol. 2003;47(2):127\u201339.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"543_CR10","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3109\/02656736.2016.1163739","volume":"32","author":"H Crezee","year":"2016","unstructured":"Crezee H, Inman BA. The use of hyperthermia in the treatment of bladder cancer. Int J Hyperth. 2016;32(4):349\u201350.","journal-title":"Int J Hyperth"},{"issue":"5","key":"543_CR11","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.juro.2015.05.102","volume":"194","author":"ED Geijsen","year":"2015","unstructured":"Geijsen ED, de Reijke TM, Koning CC. Zum Vorde Sive Vording PJ, de la rosette JJ, Rasch CR, et al. combining Mitomycin C and regional 70 MHz hyperthermia in patients with nonmuscle invasive bladder Cancer: a pilot study. J Urol. 2015;194(5):1202\u20138.","journal-title":"J Urol"},{"issue":"5","key":"543_CR12","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.3892\/or.2017.5570","volume":"37","author":"M Ba","year":"2017","unstructured":"Ba M, Cui S, Wang B, Long H, Yan Z, Wang S, et al. Bladder intracavitary hyperthermic perfusion chemotherapy for the prevention of recurrence of non-muscle invasive bladder cancer after transurethral resection. Oncol Rep. 2017;37(5):2761\u201370.","journal-title":"Oncol Rep"},{"issue":"2","key":"543_CR13","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s00345-015-1595-3","volume":"34","author":"F Soria","year":"2016","unstructured":"Soria F, Milla P, Fiorito C, Pisano F, Sogni F, Di Marco M, et al. Efficacy and safety of a new device for intravesical thermochemotherapy in non-grade 3 BCG recurrent NMIBC: a phase I-II study. World J Urol. 2016;34(2):189\u201395.","journal-title":"World J Urol"},{"key":"543_CR14","doi-asserted-by":"publisher","first-page":"262313","DOI":"10.1155\/2013\/262313","volume":"2013","author":"RA Owusu","year":"2013","unstructured":"Owusu RA, Abern MR, Inman BA. Hyperthermia as adjunct to intravesical chemotherapy for bladder cancer. Biomed Res Int. 2013;2013:262313.","journal-title":"Biomed Res Int"},{"issue":"8","key":"543_CR15","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.7314\/APJCP.2015.16.8.3241","volume":"16","author":"RG Ekin","year":"2015","unstructured":"Ekin RG, Akarken I, Cakmak O, Tarhan H, Celik O, Ilbey YO, et al. Results of Intravesical chemo-hyperthermia in high-risk non-muscle invasive bladder Cancer. Asian Pac J Cancer Prev. 2015;16(8):3241\u20135.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"4","key":"543_CR16","doi-asserted-by":"publisher","first-page":"374","DOI":"10.3109\/02656736.2016.1142618","volume":"32","author":"A Sousa","year":"2016","unstructured":"Sousa A, Pineiro I, Rodriguez S, Aparici V, Monserrat V, Neira P, et al. Recirculant hyperthermic IntraVEsical chemotherapy (HIVEC) in intermediate-high-risk non-muscle-invasive bladder cancer. Int J Hyperth. 2016;32(4):374\u201380.","journal-title":"Int J Hyperth"},{"issue":"5","key":"543_CR17","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s00345-016-1927-y","volume":"35","author":"AI Rolevich","year":"2017","unstructured":"Rolevich AI, Zhegalik AG, Mokhort AA, Minich AA, Vasilevich VY, Polyakov SL, et al. Results of a prospective randomized study assessing the efficacy of fluorescent cystoscopy-assisted transurethral resection and single instillation of doxorubicin in patients with non-muscle-invasive bladder cancer. World J Urol. 2017;35(5):745\u201352.","journal-title":"World J Urol"},{"issue":"3","key":"543_CR18","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.urology.2003.10.036","volume":"63","author":"ON Gofrit","year":"2004","unstructured":"Gofrit ON, Shapiro A, Pode D, Sidi A, Nativ O, Leib Z, et al. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer. Urology. 2004;63(3):466\u201371.","journal-title":"Urology."},{"issue":"4","key":"543_CR19","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S0022-5347(01)66225-6","volume":"155","author":"R Colombo","year":"1996","unstructured":"Colombo R, Da Pozzo LF, Lev A, Freschi M, Gallus G, Rigatti P. Neoadjuvant combined microwave induced local hyperthermia and topical chemotherapy versus chemotherapy alone for superficial bladder cancer. J Urol. 1996;155(4):1227\u201332.","journal-title":"J Urol"},{"issue":"15","key":"543_CR20","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.3748\/wjg.v16.i15.1901","volume":"16","author":"MC Ba","year":"2010","unstructured":"Ba MC, Cui SZ, Lin SQ, Tang YQ, Wu YB, Wang B, et al. Chemotherapy with laparoscope-assisted continuous circulatory hyperthermic intraperitoneal perfusion for malignant ascites. World J Gastroenterol. 2010;16(15):1901\u20137.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"543_CR21","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.3892\/or.2012.1913","volume":"28","author":"S Cui","year":"2012","unstructured":"Cui S, Ba M, Tang Y, Liu J, Wu Y, Wang B, et al. B ultrasound-guided hyperthermic intraperitoneal perfusion chemotherapy for the treatment of malignant ascites. Oncol Rep. 2012;28(4):1325\u201331.","journal-title":"Oncol Rep"},{"issue":"4","key":"543_CR22","doi-asserted-by":"publisher","first-page":"303","DOI":"10.4103\/0976-500X.119726","volume":"4","author":"J Charan","year":"2013","unstructured":"Charan J, Kantharia ND. How to calculate sample size in animal studies? J Pharmacol Pharmacother. 2013;4(4):303\u20136.","journal-title":"J Pharmacol Pharmacother"},{"issue":"4","key":"543_CR23","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1093\/ilar.43.4.244","volume":"43","author":"MF Festing","year":"2002","unstructured":"Festing MF, Altman DG. Guidelines for the design and statistical analysis of experiments using laboratory animals. ILAR J. 2002;43(4):244\u201358.","journal-title":"ILAR J"},{"issue":"1","key":"543_CR24","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/ilar.47.1.5","volume":"47","author":"MF Festing","year":"2006","unstructured":"Festing MF. Design and statistical methods in studies using animal models of development. ILAR J. 2006;47(1):5\u201314.","journal-title":"ILAR J"},{"issue":"5","key":"543_CR25","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.jaad.2012.02.010","volume":"67","author":"AP Chen","year":"2012","unstructured":"Chen AP, Setser A, Anadkat MJ, Cotliar J, Olsen EA, Garden BC, et al. Grading dermatologic adverse events of cancer treatments: the common terminology criteria for adverse events version 4.0. J Am Acad Dermatol. 2012;67(5):1025\u201339.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"543_CR26","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s00280-014-2381-4","volume":"73","author":"P Milla","year":"2014","unstructured":"Milla P, Fiorito C, Soria F, Arpicco S, Cattel L, Gontero P. Intravesical thermo-chemotherapy based on conductive heat: a first pharmacokinetic study with mitomycin C in superficial transitional cell carcinoma patients. Cancer Chemother Pharmacol. 2014;73(3):503\u20139.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"543_CR27","first-page":"179","volume":"54","author":"EA Abdelaleem","year":"2016","unstructured":"Abdelaleem EA, Naguib IA, Zaazaa HE, Hussein EA. Development and validation of HPLC and HPTLC methods for determination of Cefoperazone and its related impurities. J Chromatogr Sci. 2016;54(2):179\u201386.","journal-title":"J Chromatogr Sci"},{"issue":"11","key":"543_CR28","doi-asserted-by":"publisher","first-page":"972","DOI":"10.3109\/00207454.2015.1088848","volume":"126","author":"R Dwivedi","year":"2016","unstructured":"Dwivedi R, Singh M, Kaleekal T, Gupta YK, Tripathi M. Concentration of antiepileptic drugs in persons with epilepsy: a comparative study in serum and saliva. Int J Neurosci. 2016;126(11):972\u20138.","journal-title":"Int J Neurosci"},{"issue":"2","key":"543_CR29","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/bju.13599","volume":"119","author":"T Onishi","year":"2017","unstructured":"Onishi T, Sugino Y, Shibahara T, Masui S, Yabana T, Sasaki T. Randomized controlled study of the efficacy and safety of continuous saline bladder irrigation after transurethral resection for the treatment of non-muscle-invasive bladder cancer. BJU Int. 2017;119(2):276\u201382.","journal-title":"BJU Int"},{"key":"543_CR30","volume-title":"Clinical practice guidelines in oncology (NCCN guidelines). Bladder Cancer. Version 4.2019","author":"NCCN","year":"2019","unstructured":"NCCN. Clinical practice guidelines in oncology (NCCN guidelines). Bladder Cancer. Version 4.2019. National Comprehensive Cancer Network: Fort Washington; 2019."},{"issue":"4","key":"543_CR31","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3109\/02656736.2016.1140232","volume":"32","author":"H van Valenberg","year":"2016","unstructured":"van Valenberg H, Colombo R, Witjes F. Intravesical radiofrequency-induced hyperthermia combined with chemotherapy for non-muscle-invasive bladder cancer. Int J Hyperth. 2016;32(4):351\u201362.","journal-title":"Int J Hyperth"},{"issue":"6","key":"543_CR32","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.7314\/APJCP.2015.16.6.2297","volume":"16","author":"T Takai","year":"2015","unstructured":"Takai T, Inamoto T, Komura K, Yoshikawa Y, Uchimoto T, Saito K, et al. Feasibility of photodynamic diagnosis for challenging TUR- Bt cases including muscle invasive bladder cancer, BCG failure or 2nd-TUR. Asian Pac J Cancer Prev. 2015;16(6):2297\u2013301.","journal-title":"Asian Pac J Cancer Prev"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-019-0543-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12894-019-0543-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-019-0543-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T00:20:34Z","timestamp":1606868434000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-019-0543-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["543"],"URL":"https:\/\/doi.org\/10.1186\/s12894-019-0543-8","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"20 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Ethics Committee of Animal Experiments of Guangzhou Medical University (No. GZMU ECAE 20060326), Guangzhou, China;This study was approved by the Medical Ethics Committee of the Cancer Hospital of Guangzhou Medical University (No. GZMUMEC20060825). Written informed consent was obtained from all patients.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"126"}}